Update on the FRP Investigation

Summary by AI ^BETAClose X

SkinBioTherapeutics plc has announced that FRP Advisory is nearing the completion of its forensic investigation, with a report expected for the Board in the coming days. Following a review of these findings and consultation with external advisors, the company will finalize its HY26 results and restate its unaudited FY25 results as soon as practicable.

Disclaimer*

SkinBioTherapeutics PLC

29 April 2026

A blue text on a white background Description automatically generated

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

Update on the FRP Investigation

29 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that FRP Advisory is in the final stages of its forensic investigation and is expected to provide its report to the Board in the coming days.

Once the Board has had the opportunity to review the findings, taken appropriate advice from its external advisers, and considered the regulatory and governance implications of the investigation, it will finalise the HY26 results with the restated (unaudited) FY25 results as soon as practicable.

-Ends-

For more information please contact:

SkinBioTherapeutics plc
Martin Hunt, Executive Chairman
Rachel Parsonage, Interim CEO
Emily Bertram, CFO

ir@skinbiotix.com

Singer Capital Markets (Nominated Adviser & Broker)
Philip Davies
James Todd
Patrick Weaver

+44 (0) 020 7496 3000

Vigo Consulting
Melanie Toyne-Sewell
Rozi Morris

+44 (0) 20 7390 0230
SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix^®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix^® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END